COST COMPARISON STUDY BETWEEN A PRIVATE SECTOR AND A PUBLIC SECTOR HOSPITAL IN PESHAWAR, KHYBER PAKHTUNKHWA, PAKISTAN FOR MYOCARDIAL INFARCTION PATIENTS
PDF

How to Cite

Ayub, B., Abidullah, ., Zulkamal, ., Khan, A., Ahmed, S., Rahman, S., & Ayub, N. (2015). COST COMPARISON STUDY BETWEEN A PRIVATE SECTOR AND A PUBLIC SECTOR HOSPITAL IN PESHAWAR, KHYBER PAKHTUNKHWA, PAKISTAN FOR MYOCARDIAL INFARCTION PATIENTS. KHYBER MEDICAL UNIVERSITY JOURNAL, 7(2), 60-63. Retrieved from https://www.kmuj.kmu.edu.pk/article/view/14069

Abstract

OBJECTIVE: To determine cost comparison of private sector hospital;
North West General Hospital (NWGH) and public sector hospital; Hayat
Abad Medical Complex (HMC), for myocardial infarction (MI) patients.
Methodology: The demographic data of the patients suffering from MI were collected from NWGH and HMC Hospital and Research Center Peshawar, Khyber Pakhtunkhwa Pakistan. Frequency of MI patients were
calculated from patients suffering from cardiovascular disease (CVD),
total direct medical costs were calculated, average hospital stay as well
as the Willingness to pay were also determine.
RESULTS: Out of total 667 Cardiovascular disease (CVD) patients 241
patients were suffering from MI. Out of total 241 MI patients from both
hospitals, 74 (30.71%) get treatment from NWGH and 167 (69.29%)
get treatment from HMC. Average hospital stay of MI patients in HMC
is 3.23 days and in NWGH is 1.63 days. Total average MI medical related
cost in HMC is Pakistani Rupees (Rs.) 23650 and NWGH is Rs.
280425. Out of total 241 MI patients, 36.93% and 85.89% cannot bear
the expenses of myocardial infarction related costs of HMC and NWGH
respectively
CONCLUSION: High Cost, low rate of hospitalization, lesser average
hospital stay and larger number of patients who cannot bear the expenses of NWGH indicates that NWGH is expensive and not affordable
for major population of KPK suffering from MI.
KEY WORDS: Myocardial infarction (MeSH), Costs and Cost Analysis
(MeSH), Length of Stay (MeSH)

PDF

References

Ziauddin, Ali N, Sultan U, Haq Z. Pharmacotherapeutic study of myocardial infarction. Can J App Sci 2012; 2(1): 233-239.

Thygesen K, Alpert JS, A. S. Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction”. European Heart Journal 2012; 33: 2551–2567.

Zareef S, Jamil M, Baqai HZ, Syed NM. Frequency of various Risk Factors among Patients with Myocardial Infarction. Ann. Pak. Inst. Med. Sci. 2009; 5(3): 193-196.

Shah I, Faheem M, Khan A, Jan H, Hafizullah M. Hospital outcomes of ST-elevated myocardial infarction in patients with and without hypertension. J. Med. Sci. 2012; 20(4): 159-164.

Abbas S, Kitchlew AR, Abbas S. Disease Burden of Ischemic Heart Disease in Pakistan and its Risk Factors. Ann. Pak. Inst. Med. Sci. 2009; 5(3): 145-150.

Ashraf A, Ashraf S. Conventional cardiovascular risk factors associated with acute coronary syndrome in female patients admitted in cardiology departments Khyber teaching hospital Peshawar. Khyber Med Uinv J 2012; 4(2): 64-69.

Javaid A, Abid AR, Rizvi FH, Ahmad I. In hospital outcome of patients with acute ST- elevated myocardial infarction requiring temporary transvenous pacing. Journal of Shiekh Zayed Medical College 2011; 2(4): 217-223.

Ikramullah, Ali J, Faheem M, Qureshi S, Shah SFA, Khan SA, Hafizullah M. Frequency of complete heart block and in-hospital mortility in patiets with acute interior wall infarction. Pak Heart J 2012; 45 (04): 249–255.

Shabbir M, Azhar M, Kayani AM, Qureshi O, Mughal MM. Predictors of fatal outcomes in acute myocardial infarction. J Ayub Med Coll Abbottabad 2008; 20(3): 14-16.

Jaffery MH, Shaikh K, Baloch GH, Shah SZA. Acute myocardial infarction. Professional Med J 2014, 21(2): 258-263.

Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res 2006; 124: 235-244.

Bramkamp M, Radovanovic D, Erne P, Szucs TD. Determinants of Costs and the Length of Stay in Acute Coronary Syndromes: A Real Life Analysis of More Than 10,000 Patients. Cardiovasc Drugs Ther 2007; DOI 10.1007/s10557-007-6044-0

Tang JL, Wang WZ, An JG, Hu YH, Cheng SH, Griffiths S . How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city. International Journal of Epidemiology 2009; 1–11

Gattani SG, Patil AB, Kushare SS. PHARMACOECONOMICS: A REVIEW, Asian Journal of Pharmaceutical and Clinical Research 2009; Issue 3(2): 15-26.

Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness to pay (WTP) for one additional QALY Gained: What is the threshould of cost effectiveness?, Health Eonomics. Health Econ 2010; 19: 422-437.

Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?. Clinico Economics and Outcomes Research 2013; 5: 29–36.

I. A. Dhalla, M. A. Smith, N. K. Choudrey, A. E. Denburge. “Costs and benefits of free medication after myocardial infarction” Health Care Policy, 5(2), 68-86, (2009).

A. Desideria, P. M. Fiorettib, L. Cortigianic, D. Gregorid, C. Colettae, C. Vignaf, F. Totag, R. Rambaldih, J. Baxi, L. Celegonj, R. Bigik, E. Picanol “Cost of strategies after myocardial infarction (COSTAMI)” European Heart Journal, 24, 1630-1639, (2003).

Work published in KMUJ is licensed under a

 Creative Commons Attribution-NonCommercial 2.0 Generic License.

Creative Commons License

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.